Terran Biosciences announces publication of PCT patent application covering novel non-hallucinogenic psychoplastogens, including derivatives of DMT and ibogaine with improved pharmacokinetics and engagement at target receptors

Posted on by

NEW YORK, May 5, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of two PCT patent applications covering novel…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.